Xinnate AB
PrivateLast Round
VC Round
Dec 18, 2025
Total Funding Raised
$1.77M
Company Overview
Xinnate AB is a pharmaceutical company that develops novel peptide-based therapies for the treatment of inflammatory skin conditions and wounds.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xinnate AB Comparables
Compare Xinnate AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioMendics | 80% | |
| Aegle Therapeutics Corp | 79% | |
| TWi Biotechnology, Inc. | 78% |
Xinnate AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 18, 2025 | ||||
| VC Round | Jul 1, 2025 | ||||
| Grant | Jul 1, 2022 |
Xinnate AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| United States Department of Defense | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
CMO speaking at the EB 2026 International Congress.
- Jul 1, 2025
$3.2M round raised.
Xinnate AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access